Sotera Health Company (SHC) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: positive financial performance with strong revenue growth in some segments and improved margins, but also challenges like a net loss and declining revenue in Nelson Labs. The Q&A reveals optimism about future growth and margin improvements, yet there are uncertainties regarding legal risks and regulatory outcomes. The market cap suggests moderate reaction, and the absence of strong catalysts like new partnerships or significant guidance changes leads to a neutral prediction for stock movement.
Key Financial Performance
Total Revenues $255 million, an increase of 2.6% year-over-year (4.4% on a constant currency basis). The increase was impacted by a foreign currency headwind of 180 basis points and one less selling day compared to Q1 2024.
Adjusted EBITDA $122 million, an increase of 8.8% year-over-year (11.2% on a constant currency basis). All three business segments expanded margins, resulting in a total company adjusted EBITDA margin of 47.9%, a 276 basis point increase from Q1 2024.
Adjusted EPS $0.14, a $0.01 improvement compared to Q1 2024.
Sterigenics Revenue $170 million, a 1.9% increase year-over-year (3.9% on a constant currency basis). Growth was driven by favorable pricing of 4.1%, partially offset by unfavorable foreign currency exchange rates.
Sterigenics Segment Income $88 million, a 2.5% increase year-over-year, driven by favorable pricing, partially offset by inflation and changes in foreign exchange rates.
Nordion Revenue $33 million, a 36% increase year-over-year (40.6% on a constant currency basis). Revenue exceeded expectations due to Cobalt-60 shipments shifting from Q2 to Q1.
Nordion Segment Income $17.4 million, a 62% increase year-over-year, with segment income margin expanding nearly 860 basis points, primarily driven by volume and mix growth.
Nelson Labs Revenue $52 million, a decline of 9.3% year-over-year. This was due to a decline in expert advisory services revenue, despite favorable pricing and improved core lab testing.
Nelson Labs Segment Income $16 million, a 7% increase year-over-year, with segment income margins expanding nearly 480 basis points, driven by favorable volume and mix from improved core lab testing.
Interest Expense $41 million, improved from $42 million in Q1 2024.
Net Loss (GAAP) $13 million, or $0.05 per diluted share, compared to a net income of $6 million, or $0.02 per diluted share, in Q1 2024.
Operating Cash Flow Approximately $56 million for the quarter.
Capital Expenditures $20 million for Q1 2025.
Net Leverage Ratio 3.6 times, an improvement from 3.7 times at the end of 2024.
Available Liquidity $715 million, including over $300 million of unrestricted cash and $410 million of available capacity under the revolving line of credit.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Development: Sotera Health's teams across Nelson Labs and Sterigenics played a critical role in securing FDA clearance for the first ever bionic pancreas, demonstrating their integrated expertise in science, quality, and regulatory navigation.
Market Positioning: Sterigenics holds a leading position in a $4.5 billion sterilization service addressable market, benefiting from positive trends such as an aging population and increased healthcare spending.
Revenue Growth Outlook: The company expects total revenues to grow in the range of 4% to 6% on a constant currency basis for 2025.
Operational Efficiency: Nelson Labs achieved 479 basis point margin expansion, marking the third consecutive quarter of year-over-year margin improvement.
Capital Expenditures: Capital expenditures for Q1 2025 totaled $20 million, with expectations to be in the range of $190 million to $210 million for the full year.
Strategic Focus: The company is prioritizing organic growth, deleveraging, and opportunistic M&A as part of its capital deployment strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The company operates in a highly regulated environment, particularly in the sterilization and healthcare sectors, which can pose risks related to compliance and operational requirements.
Foreign Exchange Risks: Foreign currency presented a headwind of 180 basis points for the quarter, particularly affecting the Canadian-based Nordion business.
Tariff Policies: Current tariff policies are not expected to have a material impact on the business, but the company remains vigilant regarding potential changes.
Supply Chain Challenges: There is a noted risk associated with Russian supplied Cobalt, with an approximate risk of 0% to 2% of total company 2025 revenue, although no disruptions have been experienced to date.
Economic Factors: The company faces inflationary pressures that can impact pricing and margins, as seen in the segment income growth being partially offset by inflation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For full year 2025, total revenues are expected to grow in the range of 4% to 6% on a constant currency basis.
Adjusted EBITDA Growth: Adjusted EBITDA growth is projected in the range of 4.5% to 6.5% on a constant currency basis for 2025.
Capital Expenditures: Capital expenditures are expected to be in the range of $190 million to $210 million in 2025, decreasing to approximately $110 million in 2027.
Free Cash Flow: The company aims to generate between $500 million to $600 million in free cash flow over the next three years.
Operational Excellence: Focus on driving operational excellence to enhance free cash flow.
Market Position: Sterigenics holds a leading position in a $4.5 billion sterilization service addressable market.
Adjusted EPS: Adjusted EPS is expected to be in the range of $0.70 to $0.76 for 2025.
Interest Expense: Interest expense is projected to be between $155 million and $165 million.
Effective Tax Rate: The effective tax rate applicable to adjusted net income is expected to be in the range of 33% to 35%.
Net Leverage Ratio: A slight improvement in the net leverage ratio is anticipated in 2025.
Nordion Revenue Outlook: Nordion expects constant currency full year revenue growth in the mid-single digits.
Nelson Labs Revenue Outlook: Nelson Labs anticipates full year 2025 constant currency revenue growth of low to mid-single digits.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company did not announce any share repurchase program during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you just talk through the tariff side? Are there any small impacts that you guys are offsetting?
A:We're confident we'll not have a material impact on the company. The largest component we are following was Cobalt from Canada to the U.S. under USMCA, and we don't see it as a material item.
Q:Any change in your thinking about Sterigenics recovery?
A:We're more optimistic on the volumes. We saw improvement throughout the quarter and are optimistic based on what we are seeing in early stages of the second quarter.
Q:Can you expand on the factors driving Nelson Labs margin trends?
A:New regulation, new product spend, and sterilization volumes are driving improvement. We expect routine and validation volumes to improve throughout the year.
Q:Are there particular end markets driving Sterigenics volume growth?
A:Bioprocessing has had significant growth, but it's a small portion of our total business. The underlying trends on our core customer base are strong.
Q:Can you talk about your legal strategy and risk assessment on ongoing cases?
A:I'm not going to get into a ton of details. We are confident that at this level of emissions, we're not causing cancer. We'll vigorously defend ourselves.
Q:What about cross-selling initiatives between Nelson and Sterigenics?
A:We've had incentives in place for the last couple of years and are making nice progress on the service side.
Q:What should we expect from a 2Q margin perspective?
A:We expect margin improvement throughout the year to come from the Nelson side.
Q:What causes your volume disconnect between good med device volumes and yours?
A:We have a couple of customers with challenges, but we're seeing volumes ramp up in other areas.
Q:How do you assess the pressure on the broader biopharma R&D product development cycle?
A:We're not expecting a big step back in bioprocessing. We're seeing good visibility from customers.
Q:Are you at a defensible level now on price for Sterigenics?
A:Our price in the quarter for Sterigenics was at 4%, consistent with our long-range target.
Q:Any updates on potential additional lawsuits in states like North Carolina and Texas?
A:There's no active litigation in those areas, but we feel good about our ability to succeed.
Q:What do you expect from the review of the ethylene oxide rule and regulations?
A:It's uncertain at this point what they are going to do. We're continuing to move forward with our NESHAP improvements.
Q:Is the 4% constant currency growth in Sterigenics year-on-year adjusted for the last day?
A:Yes, that's how we think about it.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specifics of their legal strategy and ongoing cases, stating they would not get into details and referring to existing disclosures. Additionally, there was a lack of clarity on the expected outcomes of the EPA's review of the ethylene oxide rule, indicating uncertainty without providing specific insights.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Sotera
Canadian Nordion
Cobalt Canada
Cobalt disruption
Cobalt shipment
Cobalt tariff
ET Sotera
Interest expense
Lab
Lyons
Peterson
President Investor
Sotera Health
Sterigenics
amendment
basis currency
core lab
currency digit
decline service
digit line
environment
expectation
headwind quarter
health
improvement leverage
insulin
investor section
lab optimization
lab testing
line digit
margin expansion
mission
point increase
product
requirement
sterilization
tariff policy
team
testing volume
time
value
SHC Transcript
Sotera Health Company (SHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Sotera Health Company (SHC) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals strong financial metrics, including raised revenue and EBITDA growth outlooks, improved net leverage ratio, and increased adjusted EPS guidance. Despite some concerns, such as margin compression and Q4 pullback, the overall sentiment is positive, with consistent performance across key areas and confidence in long-term growth. The market cap suggests moderate volatility, leading to a positive stock price prediction (2%-8%) over the next two weeks.
Sotera Health Company (SHC) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary and Q&A indicate stable financial performance, with positive operating cash flow and improved net leverage ratio. Despite limited guidance for 2026, there is optimism in product development and market strategy, particularly with Sterigenics and Nelson Labs. The company's strong liquidity position and ongoing investments in capacity expansion further support a positive outlook. Given the market cap of approximately $3.37 billion, the stock is likely to experience a moderate positive reaction in the range of 2% to 8% over the next two weeks.
Sotera Health Company (SHC) Q1 2025 Earnings Call Transcript
Unknown5-2
The earnings call presents a mixed picture: positive financial performance with strong revenue growth in some segments and improved margins, but also challenges like a net loss and declining revenue in Nelson Labs. The Q&A reveals optimism about future growth and margin improvements, yet there are uncertainties regarding legal risks and regulatory outcomes. The market cap suggests moderate reaction, and the absence of strong catalysts like new partnerships or significant guidance changes leads to a neutral prediction for stock movement.
SHC Slides
SHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
